Literature DB >> 8562758

Delirium associated with acyclovir treatment in a patient with renal failure.

S G Revankar1, A L Applegate, D M Markovitz.   

Abstract

Neurotoxicity associated with acyclovir use is infrequently encountered. However, the half-life of acyclovir is greatly prolonged in patients with end-stage renal disease, predisposing these patients to neurological side effects that are generally reversible but occasionally severe. In general, renal dialysis effectively decreases the serum level of acyclovir, which correlates with toxicity. We report an unusual case of delirium and coma in a patient undergoing hemodialysis who was receiving what appeared to be an appropriately adjusted dose of acyclovir.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8562758     DOI： 10.1093/clinids/21.2.435

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  5 in total

Review 1.  The use of antiviral drugs during the neonatal period.

Authors:  Richard J Whitley
Journal:  Clin Perinatol       Date:  2012-01-21       Impact factor: 3.430

2.  Characterization of a proteolytically stable D-peptide that suppresses herpes simplex virus 1 infection: implications for the development of entry-based antiviral therapy.

Authors:  Dinesh Jaishankar; Abraam M Yakoub; Anita Bogdanov; Tibor Valyi-Nagy; Deepak Shukla
Journal:  J Virol       Date:  2014-11-26       Impact factor: 5.103

Review 3.  Resolution of acyclovir-associated neurotoxicity with the aid of improved clearance estimates using a Bayesian approach: A case report and review of the literature.

Authors:  W A Watson; N J Rhodes; I A Echenique; M P Angarone; M H Scheetz
Journal:  J Clin Pharm Ther       Date:  2017-03-29       Impact factor: 2.512

Review 4.  Anti-herpes viruses agents.

Authors:  N M Abdel-Haq; B I Asmar
Journal:  Indian J Pediatr       Date:  2001-07       Impact factor: 5.319

5.  The Efficacy of Amenamevir for the Treatment of Disseminated Herpes Zoster Complicated with Probable Varicella-zoster Pneumonia in an Immunocompromised Patient.

Authors:  Hiroki Kobayashi; Yusuke Yoshida; Tomoki Komoshita; Harumichi Suma; Yohei Hosokawa; Yoshikazu Hirose; Tomohiro Sugimoto; Sho Mokuda; Shintaro Hirata; Eiji Sugiyama
Journal:  Intern Med       Date:  2021-11-13       Impact factor: 1.282
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.